During the last years a considerable therapeutic progress in melanoma patients with the RAF V600E mutation via RAF/MEK pathway inhibition and immuno-therapeutic modalities has been witnessed. However, the majority of patients relapse after therapy. Therefore, a deeper understanding of the pathways driving oncogenicity and metastasis of melanoma is of paramount importance. In this review, we summarize microRNAs modulating tumor growth, metastasis, or both, in preclinical melanoma-related in vivo models and possible clinical impact in melanoma patients as modalities and targets for treatment of melanoma. We have identified miR-199a (ApoE, DNAJ4), miR-7-5p (RelA), miR-98a (IL6), miR-219-5p (BCL2) and miR-365 (NRP1) as possible targets to be scrutinized in further target validation studies.Copyright? 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
展开▼
机译：在过去几年中，通过RAF / MEK途径抑制和免疫治疗方式的RAF v600E突变具有相当大的治疗进展。然而，大多数患者治疗后复发。因此，更深入地理解促进黑色素瘤的致癌性和转移的途径至关重要。在本次综述中，我们总结了在体内模型中突出的黑色素瘤相关的肿瘤生长，转移或两者以及黑素瘤患者可能的临床影响作为治疗黑素瘤的态度和靶标。我们已经确定了MiR-199A（ApoE，DNAJ4），miR-7-5p（Rela），miR-98a（IL6），miR-219-5p（Bcl2）和miR-365（NRP1），以便仔细审查靶标进一步的目标验证研究.Copyright？ 2020年，国际抗癌研究所（George J. Delinasios博士），保留所有权利。
展开▼
